FIELD: biotechnology.
SUBSTANCE: antibodies that bind to human beta 1 tryptase and pharmaceutical compositions including them are proposed. Nucleic acids, expression vectors and host cells intended for the production of the specified antibodies are also proposed.
EFFECT: invention provides for binding to human beta 1 tryptase with high affinity and inhibiting tryptase activity in vivo.
72 cl, 32 dwg, 17 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTIBODIES AGAINST HtrA1 AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2750285C2 |
